

---

---

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

**CONCORD MEDICAL SERVICES HOLDINGS LIMITED**

(Name of Issuer)

---

**Class A ordinary shares, par value US\$0.0001 per share**

(Title of Class of Securities)

---

**206277 105<sup>(1)</sup>**

(CUSIP Number)

---

**SZE Mei Ming  
Fosun International Limited  
Room 808  
ICBC Tower  
3 Garden Road, Central  
Hong Kong, China  
(852) 2509 3228**

**With a copy to:  
Gregory Wang, Esq.  
Reed Smith Richards Butler  
20/F, Alexandra House  
18 Chater Road, Central  
Hong Kong, China  
(852) 2507 9869**

---

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**December 7, 2018**

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>(1)</sup> This CUSIP number applies to the Issuer's American depositary shares ("ADSs"), each representing three Class A ordinary shares of the Issuer.

---

(1)	NAME OF REPORTING PERSONS	
	Fosun International Limited	
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
	(a)	<input checked="" type="checkbox"/>
	(b)	<input type="checkbox"/>
(3)	SEC USE ONLY	
(4)	SOURCE OF FUNDS	
	WC	
(5)	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) <input type="checkbox"/>	
(6)	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Hong Kong	
	Number of Shares	(7) SOLE VOTING POWER
		0
	Beneficially Owned by Each Reporting Person With	(8) SHARED VOTING POWER
		13,086,350
		(9) SOLE DISPOSITIVE POWER
		0
		(10) SHARED DISPOSITIVE POWER
		13,086,350
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	13,086,350	
(12)	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
	<input type="checkbox"/>	
(13)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	15.5% <sup>(1)</sup>	
(14)	TYPE OF REPORTING PERSON	
	CO	

(1) This percentage is calculated based on 84,368,529 Class A ordinary shares, par value \$0.0001 per share (the "Ordinary Shares") of Concord Medical Services Holdings Limited (the "Issuer") outstanding as of December 7, 2018, as disclosed in the Issuer's Form 6-K filed with the Securities and Exchange Commission (the "SEC") on December 7, 2018.

(1)	NAME OF REPORTING PERSONS	
	Fosun Industrial Holdings Limited	
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
	(a) <input checked="" type="checkbox"/>	
	(b) <input type="checkbox"/>	
(3)	SEC USE ONLY	
(4)	SOURCE OF FUNDS	
	AF	
(5)	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	<input type="checkbox"/>
(6)	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Hong Kong	
	Number of Shares	(7) SOLE VOTING POWER
		0
	Beneficially Owned by Each Reporting Person With	(8) SHARED VOTING POWER
		13,086,350
		(9) SOLE DISPOSITIVE POWER
		0
		(10) SHARED DISPOSITIVE POWER
		13,086,350
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	13,086,350	
(12)	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	<input type="checkbox"/>
(13)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	15.5% <sup>(1)</sup>	
(14)	TYPE OF REPORTING PERSON	
	CO	

(1) This percentage is calculated based on 84,368,529 Ordinary Shares of the Issuer outstanding as of December 7, 2018, as disclosed in the Issuer's Form 6-K filed with the SEC on December 7, 2018.

(1)	NAME OF REPORTING PERSONS	
	Oasis Inspire Limited	
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	
	(a) <input checked="" type="checkbox"/>	
	(b) <input type="checkbox"/>	
(3)	SEC USE ONLY	
(4)	SOURCE OF FUNDS	
	AF	
(5)	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	<input type="checkbox"/>
(6)	CITIZENSHIP OR PLACE OF ORGANIZATION	
	British Virgin Islands	
	Number of Shares	(7) SOLE VOTING POWER 0
	Beneficially Owned by Each Reporting Person With	(8) SHARED VOTING POWER 13,086,350
		(9) SOLE DISPOSITIVE POWER 0
		(10) SHARED DISPOSITIVE POWER 13,086,350
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	13,086,350
(12)	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	<input type="checkbox"/>
(13)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	15.5% <sup>(1)</sup>
(14)	TYPE OF REPORTING PERSON	CO

(1) This percentage is calculated based on 84,368,529 Ordinary Shares of the Issuer outstanding as of December 7, 2018, as disclosed in the Issuer's Form 6-K filed with the SEC on December 7, 2018.

### **Explanatory Note**

This Amendment No. 1 to statement on Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D filed with the SEC on November 13, 2017 (the “Original Schedule 13D”, and as amended and supplemented by this Amendment No. 1, the “Schedule 13D”), and is being filed on behalf of the Reporting Persons in respect of the Ordinary Shares of the Issuer.

This Amendment No. 1 is being filed by the Reporting Persons solely to report changes to the beneficial ownership as a result of change in the aggregate number of outstanding Ordinary Shares of the Issuer as reported in its Form 6-K filed with the SEC on December 7, 2018.

Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used but not defined in this Amendment No. 1 have the respective meanings set forth in the Original Schedule 13D.

**Item 5. Interest in Securities of the Issuer.**

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) See Items 11 and 13 of the cover pages to this Schedule 13D for the aggregate number and percentage of Ordinary Shares that are beneficially owned by each Reporting Person as of January 16, 2019.

(b) See Items 7 through 10 of the cover pages to this Schedule 13D for the number of Ordinary Shares that are beneficially owned by each Reporting Person as of January 16, 2019 as to which there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition.

(c) The Reporting Persons have not effected any transactions in the Ordinary Shares or ADSs during the past 60 days.

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Schedule 13D.

(e) Not applicable.

**Item 7. Material to be Filed as Exhibits.**

Item 7 of the Schedule 13D is hereby amended and restated in its entirety as follows:

EXHIBIT 99.1 Joint Filing Agreement dated as of November 13, 2017, by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.2 List of the directors and executive officers of each Reporting Person, persons controlling any Reporting Person and the directors and executive officers of persons in control of any Reporting Person.

EXHIBIT 99.3 Share Purchase Agreement dated October 31, 2017 (incorporated by reference to Exhibit 99.3 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.4 Controlling Shareholder's Undertaking Letter dated October 31, 2017 (incorporated by reference to Exhibit 99.4 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

EXHIBIT 99.5 Issuer's Undertaking Letter dated October 31, 2017 (incorporated by reference to Exhibit 99.5 to the Original Schedule 13D filed on November 13, 2017 with the SEC).

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 16, 2019

**FOSUN INTERNATIONAL LIMITED**

By: /s/ SZE Mei Ming

Name: SZE Mei Ming

Title: Company Secretary

**FOSUN INDUSTRIAL HOLDINGS LIMITED**

By: /s/ CHEN Qiyu

Name: CHEN Qiyu

Title: Director

**OASIS INSPIRE LIMITED**

By: /s/ Yanxiang LU

Name: Yanxiang LU

Title: Director



## Fosun International Limited

<b>Name</b>	<b>Business Address</b>	<b>Present Principal Employment</b>	<b>Citizenship</b>
Guo Guangchang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Chairman of Fosun International	China
Wang Qunbin	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Chief Executive Officer of Fosun International	China
Chen Qiyu	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-President of Fosun International	China
Xu Xiaoliang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Co-President of Fosun International	China
Qin Xuatang	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Senior Vice President of Fosun International	China
Wang Can	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director, Senior Vice President and Chief Financial Officer of Fosun International	China
Gong Ping	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Executive Director and Senior Vice President of Fosun International	China
Zhang Shengman	N/A	Independent Non-executive Director of Fosun International	Hong Kong
Zhang Huaqiao	N/A	Independent Non-executive Director of Fosun International	Hong Kong
David T. Zhang	26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong	Independent Non-executive Director of Fosun International; Partner of Kirkland & Ellis LLP	Hong Kong
Yang Chao	N/A	Independent Non-executive Director of Fosun International	China
Lee Kai-Fu	10/F, Dinghao Tower Block A, No. 3 Haidian Street, Haidian District, Beijing, China	Independent Non-executive Director of Fosun International; Chairman of Sinovation Ventures (Beijing) Enterprise Management Co., Ltd.	Republic of China

**Fosun Industrial Holdings Limited**

<b>Name</b>	<b>Business Address</b>	<b>Present Principal Employment</b>	<b>Citizenship</b>
CHEN Qiyu	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director of Fosun Industrial Holdings Limited	China
Lui Man Yi	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director of Fosun Industrial Holdings Limited	Hong Kong
Law Tsz Kwan Iris	Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong	Director of Fosun Industrial Holdings Limited	Hong Kong

Fosun Industrial Holdings Limited is wholly owned by Fosun International Limited as of January 16, 2019.

---

**Oasis Inspire Limited**

<b>Name</b>	<b>Business Address</b>	<b>Present Principal Employment</b>	<b>Citizenship</b>
Yanxiang LU	17/F, Tower S1, Bund Finance Center, 600 East Zhongshan No.2 Road, Shanghai, China	Director of Oasis Inspire Limited	Hong Kong

Oasis Inspire Limited is directly wholly owned by Fosun Industrial Holdings Limited and indirectly wholly owned by Fosun International Limited as of January 16, 2019.

---